Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 21083

Negotiation Status:

Concluded with an LOI

Indication(s):

Renal Cell Carcinoma

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0132-000

pCPA Engagement Letter Issued:

2018-12-28

Negotiation Process Concluded:

2019-03-20